Matches in DBpedia 2016-04 for { <http://dbpedia.org/resource/EPI-506> ?p ?o }
Showing triples 1 to 22 of
22
with 100 triples per page.
- EPI-506 abstract "EPI-506 (developed by Essa Pharma) is an experimental compound in phase I/II development for prostate cancer. It is the successor of EPI-001 and targets the N-terminal domain of the androgen receptor. This mechanism of action is believed to allow the drug to block signaling from the androgen receptor and its splice variants.".
- EPI-506 wikiPageID "49581858".
- EPI-506 wikiPageLength "1631".
- EPI-506 wikiPageOutDegree "7".
- EPI-506 wikiPageRevisionID "707717051".
- EPI-506 wikiPageWikiLink Alternative_splicing.
- EPI-506 wikiPageWikiLink Androgen_receptor.
- EPI-506 wikiPageWikiLink Category:Pharmacology.
- EPI-506 wikiPageWikiLink EPI-001.
- EPI-506 wikiPageWikiLink Essa_Pharma.
- EPI-506 wikiPageWikiLink N-terminus.
- EPI-506 wikiPageWikiLink Prostate_cancer.
- EPI-506 wikiPageWikiLinkText "EPI-506".
- EPI-506 wikiPageUsesTemplate Template:Pharma-stub.
- EPI-506 wikiPageUsesTemplate Template:Reflist.
- EPI-506 subject Category:Pharmacology.
- EPI-506 hypernym Compound.
- EPI-506 type ChemicalCompound.
- EPI-506 comment "EPI-506 (developed by Essa Pharma) is an experimental compound in phase I/II development for prostate cancer. It is the successor of EPI-001 and targets the N-terminal domain of the androgen receptor. This mechanism of action is believed to allow the drug to block signaling from the androgen receptor and its splice variants.".
- EPI-506 label "EPI-506".
- EPI-506 wasDerivedFrom EPI-506?oldid=707717051.
- EPI-506 isPrimaryTopicOf EPI-506.